AlgoTx

We’ve reached a major milestone with the completion of the Last Patient Last Visit in our Phase II ACT trial, addressing the important unmet need of Chemotherapy-Induced Peripheral Neuropathy (#CIPN)! This double-blind, placebo-controlled study investigates the efficacy and safety of ATX01 and has included 276 patients in over 40 centers in the US and 6 European countries. With ATX01’s selective action on nociceptive sodium channels, it has potential to offer a non-opioid, targeted treatment for CIPN that minimizes toxicity through limited systemic exposure. As we look forward to sharing the trial data and advancing to the next phase, it’s fitting to highlight this progress during #PainAwarenessMonth, a time to focus on conditions like CIPN that have a profound impact on patients’ lives. 🔗 Read the press release: https://lnkd.in/eWdgmy52 #Biotech #Pharma #Innovation #ClinicalTrials #Oncology #NeuropathicPain #WorldCancerResearchDay Peripheral Nerve Society International Association for the Study of Pain Stéphane Thiroloix Philippe Picaut

Catch us at Pain Therapeutics Summit in Boston on October 28-29 where Philippe Picaut will be sharing key updates on our progress towards the next stage of our "ACT" trial for ATX01, our first in class pain therapeutic. Targeting Chemotherapy-Induced Peripheral Neuropathy (#CIPN), ATX01 is a non-opioid topical pain therapeutic that selectively targets nociceptive sodium channels involved in pain signaling, aiming to deliver effective pain relief while minimizing systemic exposure and potential toxicity. We recently completed last patient last visit for our Phase II trial and are now eagerly anticipating the forthcoming data, in the hope of providing a safe and effective solution for patients suffering from CIPN. 🔗 #PainTherapeuticsSummit: https://lnkd.in/ei64qaxY #Biotech #Pharma #ClinicalTrials #NeuropathicPain #Cancer #Oncology

Stéphane Thiroloix is at BioEurope 2024 in Stockholm from 4-6 November! Catch the latest updates on our Phase II "ACT" trial for ATX01, targeting Chemotherapy-Induced Peripheral Neuropathy (#CIPN). We recently achieved a key milestone with the completion of the Last Patient Last Visit (LPLV). 🤝 https://lnkd.in/dRGyPtmn As we advance towards pivotal data, we’re focused on delivering the first approved treatment for CIPN – where none currently exists. ATX01 is a high-concentration, non-opioid topical treatment that selectively targets nociceptive sodium channels involved in pain signaling. It offers the potential for effective pain relief from CIPN with minimal systemic exposure and toxicity. 🔗 Join #BioEurope2024: https://lnkd.in/dnuNZ2D 🤝 Schedule a meeting with Stéphane: https://lnkd.in/dRGyPtmn #Biotech #Pharma #Innovation #NeuropathicPain #CancerResearch Informa Connect Life Sciences

September is #PainAwarenessMonth, and this week we are highlighting the struggles of those living with #ChronicPain. It’s a critical time to shed light on the impact of chemotherapy-induced peripheral neuropathy (#CIPN) - hear first hand about the pain and challenges patients face. 👇 Their stories are a powerful reminder of why finding an effective treatment is so urgent. Two in three chemotherapy patients will experience CIPN and in one third of of them, CIPN will become chronic, lasting at least one year beyond the end of chemotherapy. Sadly, there is no cure. We’re pioneering a potential solution. ATX01is a first-in-class non-opioid, locally-acting treatment for CIPN. We’re anticipating data from the Phase 2-3 "ACT" trial in Q1 2025. Let’s bring hope and relief to those who need it most. #IASP #PainIsReal #Biotech #Pharma #NeuropathicPain #ClinicalTrial Peripheral Nerve Society, International Association for the Study of Pain, Dr. Julio C. Paez MD

We’re heading to #ESMO24 in Barcelona from 13-17 September! Catch our CMO Gabriel Fox there. We are looking forward to discussing the challenges of Chemotherapy-Induced Peripheral Neuropathy (#CIPN) with leading experts in oncology. Our lead product, ATX01, is breaking new ground as a first-in-class topical treatment for CIPN. With FDA fast track status and ongoing progress in our Phase 2-3 "ACT" clinical trials, we are on track to deliver  pivotal data in Q1 2025. 📧 contact@algotx.com 🔬Find out more about our treatment for CIPN: www.algotx.com 🔗 Join ESMO Congress 2024: https://lnkd.in/eSBEG7fw ESMO - European Society for Medical Oncology Oncology #Biotech #Pharma #Innovation #NeuropathicPain #Chemotherapy

We are at #MASCC2024 from June 27-29 in Lille! Catch Philippe Picaut and Gabriel Fox to hear about ATX01, our first in class treatment for Chemotherapy-Induced Peripheral Neuropathic Pain (#CIPN). CIPN is a common complication arising from treatment with many anti-cancer agents and has no specific treatment. Our therapeutic has secured #FDA fast track status and we’ve completed recruitment for our phase 2-3 "ACT" #clinicaltrial! With pivotal data anticipated in Q1 2025, we can’t wait to share how we are helping patients through the pain of #chemotherapy. 📧 contact@algotx.com 🔬Find out more about our treatment for CIPN: www.algotx.com 🔗 #MASCC2024: https://lnkd.in/ete4_vNM #Biotech #Innovation #NeuropathicPain #Cancer The Multinational Association of Supportive Care in Cancer (MASCC)

✨It’s amazing what you can achieve working together to advance modern medicine. Recruitment of all 276 patients has been completed in our pivotal phase 2 “ACT” clinical trial of ATX01, as a first in class non opioid treatment for Chemotherapy-Induced Peripheral Neuropathic Pain (#CIPN). We thank all the 41 clinical sites across the USA and Europe, the people and the patients involved in the study that worked hard to meet this important milestone. We eagerly anticipate sharing the potential impact of this treatment for patients battling # NeuropathicPain in Q1 2025. With no specific treatment currently available for #CIPN, our program has secured #FDA fast track development. 🔬Full trial details: https://lnkd.in/ekMN8xjC 📧 contact@algotx.com #Biotech #Pharma #Innovation #Cancer #Oncology

Catch Stéphane Thiroloix at #PNS2024 this month to hear about ATX01, our first in class solution for Chemotherapy-Induced Peripheral Neuropathic Pain (#CIPN). With no current cure for #CIPN, our solution has secured #FDA fast track development status. We anticipate pivotal clinical data from our phase 2-3 "ACT" clinical trial in Q1 2025, and we’re looking forward to sharing what this means for patients battling #NeuropathicPain. 📧 contact@algotx.com 🔬Find out more about our treatment for CIPN: www.algotx.com 🔗 #PNS2024: https://lnkd.in/g55GUG6R #Biotech #Pharma #Innovation Peripheral Nerve Society

Join us in San Diego from June 3-6 for BIO International, the largest and most comprehensive event in #biotech! https://lnkd.in/efSF-Aic ATX01 is our pioneering solution for Chemotherapy-Induced Peripheral Neuropathic Pain (#CIPN) with FDA fast track status, paving the way for groundbreaking advancements in complex pain management. Catch up with our founder & CEO Stéphane Thiroloix as he shares the latest on our preparations for pivotal clinical data expected from our phase 2-3 "ACT" clinical trial in CIPN during the second half of 2024. 🤝 Join Stéphane on-site: https://lnkd.in/efSF-Aic 🔗 Register for #BIO2024 now: https://lnkd.in/gSXh3GTj #Pharma #NeuropathicPain #Innovation Biotechnology Innovation Organization

With great sadness we wish to inform you that Olivier Bohuon passed away on Sunday.    Olivier was the Co-Founder of AlgoTx and a member of our Board of Directors. Those who met him know he was an exceptional man in both the personal and professional spheres. We will miss him dearly, and our efforts to develop ATX01 will be a tribute to his courage.